 DUBLIN, April 7, 2021 PRNewswire -- Alkermes plc Nasdaq: ALKS today announced that it has entered into a clinical trial collaboration and supply agreement with MSD a tradename of Merck Co., Inc. Kenilworth, NJ, USA for a planned phase 3 study to evaluate nemvaleukin alfa nemvaleukin, formerly referred to as ALKS 4230, Alkermes novel investigational engineered interleukin-2 IL-2 variant immunotherapy, in combination with MSDs KEYTRUDA pembrolizumab, in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer. Under the terms of the agreement, Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021. 